Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial is studying how well giving dinaciclib works in treating patients with
relapsed or refractory multiple myeloma. Dinaciclib may stop the growth of cancer cells by
clocking some of the enzymes needed for cell growth.